Hormone therapy for prostate cancer and the risk of stroke

A 5-year follow-up study

Shiu Dong Chung, Yi Kuang Chen, Fang Jen Wu, Herng Ching Lin

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objective To examine the 5-year risk of stroke among patients with prostate cancer (PC) receiving androgen deprivation therapy (ADT) in Taiwan, using a population-based dataset. Patients and Methods This prospective case-control study used data sourced from the Longitudinal Health Insurance Database. The study included 365 patients with PC; 64 (17.6%) received ADT for more than 1 month. Cox proportional hazards regression was used to evaluate the association between ADT and the risk of stroke during the subsequent 5-year follow-up period, after adjusting for sociodemographic characteristics and hypertension, diabetes, coronary heart disease, heart failure, atrial fibrillation and hyperlipidaemia. Results In the total sample of 365 patients with PC, 68 (18.6%) patients had strokes during the 5-year follow-up period. These included 11 patients with PC who received ADT (17.2% of all patients who received ADT) and 57 patients who did not receive ADT (18.9% of patients who did not receive ADT). After adjusting for potential confounders, no significant difference in the hazard of stroke was found between patients with PC who did and did not receive ADT (hazard ratio, 1.09; 95% confidence interval, 0.80-1.50). Conclusions There was no significant difference in the risk of stroke between ethnic Chinese patients with PC who did and did not receive ADT, after adjusting for potential confounders.

Original languageEnglish
Pages (from-to)1001-1005
Number of pages5
JournalBJU International
Volume109
Issue number7
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Prostatic Neoplasms
Androgens
Stroke
Hormones
Therapeutics
Health Insurance
Hyperlipidemias
Taiwan
Atrial Fibrillation
Coronary Disease
Case-Control Studies
Heart Failure
Databases
Confidence Intervals
Hypertension

Keywords

  • androgen deprivation therapy
  • epidemiology
  • prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Hormone therapy for prostate cancer and the risk of stroke : A 5-year follow-up study. / Chung, Shiu Dong; Chen, Yi Kuang; Wu, Fang Jen; Lin, Herng Ching.

In: BJU International, Vol. 109, No. 7, 04.2012, p. 1001-1005.

Research output: Contribution to journalArticle

Chung, Shiu Dong ; Chen, Yi Kuang ; Wu, Fang Jen ; Lin, Herng Ching. / Hormone therapy for prostate cancer and the risk of stroke : A 5-year follow-up study. In: BJU International. 2012 ; Vol. 109, No. 7. pp. 1001-1005.
@article{ff1ad5ab06e64dbc9e2e4c49afc359eb,
title = "Hormone therapy for prostate cancer and the risk of stroke: A 5-year follow-up study",
abstract = "Objective To examine the 5-year risk of stroke among patients with prostate cancer (PC) receiving androgen deprivation therapy (ADT) in Taiwan, using a population-based dataset. Patients and Methods This prospective case-control study used data sourced from the Longitudinal Health Insurance Database. The study included 365 patients with PC; 64 (17.6{\%}) received ADT for more than 1 month. Cox proportional hazards regression was used to evaluate the association between ADT and the risk of stroke during the subsequent 5-year follow-up period, after adjusting for sociodemographic characteristics and hypertension, diabetes, coronary heart disease, heart failure, atrial fibrillation and hyperlipidaemia. Results In the total sample of 365 patients with PC, 68 (18.6{\%}) patients had strokes during the 5-year follow-up period. These included 11 patients with PC who received ADT (17.2{\%} of all patients who received ADT) and 57 patients who did not receive ADT (18.9{\%} of patients who did not receive ADT). After adjusting for potential confounders, no significant difference in the hazard of stroke was found between patients with PC who did and did not receive ADT (hazard ratio, 1.09; 95{\%} confidence interval, 0.80-1.50). Conclusions There was no significant difference in the risk of stroke between ethnic Chinese patients with PC who did and did not receive ADT, after adjusting for potential confounders.",
keywords = "androgen deprivation therapy, epidemiology, prostate cancer",
author = "Chung, {Shiu Dong} and Chen, {Yi Kuang} and Wu, {Fang Jen} and Lin, {Herng Ching}",
year = "2012",
month = "4",
doi = "10.1111/j.1464-410X.2011.10459.x",
language = "English",
volume = "109",
pages = "1001--1005",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Hormone therapy for prostate cancer and the risk of stroke

T2 - A 5-year follow-up study

AU - Chung, Shiu Dong

AU - Chen, Yi Kuang

AU - Wu, Fang Jen

AU - Lin, Herng Ching

PY - 2012/4

Y1 - 2012/4

N2 - Objective To examine the 5-year risk of stroke among patients with prostate cancer (PC) receiving androgen deprivation therapy (ADT) in Taiwan, using a population-based dataset. Patients and Methods This prospective case-control study used data sourced from the Longitudinal Health Insurance Database. The study included 365 patients with PC; 64 (17.6%) received ADT for more than 1 month. Cox proportional hazards regression was used to evaluate the association between ADT and the risk of stroke during the subsequent 5-year follow-up period, after adjusting for sociodemographic characteristics and hypertension, diabetes, coronary heart disease, heart failure, atrial fibrillation and hyperlipidaemia. Results In the total sample of 365 patients with PC, 68 (18.6%) patients had strokes during the 5-year follow-up period. These included 11 patients with PC who received ADT (17.2% of all patients who received ADT) and 57 patients who did not receive ADT (18.9% of patients who did not receive ADT). After adjusting for potential confounders, no significant difference in the hazard of stroke was found between patients with PC who did and did not receive ADT (hazard ratio, 1.09; 95% confidence interval, 0.80-1.50). Conclusions There was no significant difference in the risk of stroke between ethnic Chinese patients with PC who did and did not receive ADT, after adjusting for potential confounders.

AB - Objective To examine the 5-year risk of stroke among patients with prostate cancer (PC) receiving androgen deprivation therapy (ADT) in Taiwan, using a population-based dataset. Patients and Methods This prospective case-control study used data sourced from the Longitudinal Health Insurance Database. The study included 365 patients with PC; 64 (17.6%) received ADT for more than 1 month. Cox proportional hazards regression was used to evaluate the association between ADT and the risk of stroke during the subsequent 5-year follow-up period, after adjusting for sociodemographic characteristics and hypertension, diabetes, coronary heart disease, heart failure, atrial fibrillation and hyperlipidaemia. Results In the total sample of 365 patients with PC, 68 (18.6%) patients had strokes during the 5-year follow-up period. These included 11 patients with PC who received ADT (17.2% of all patients who received ADT) and 57 patients who did not receive ADT (18.9% of patients who did not receive ADT). After adjusting for potential confounders, no significant difference in the hazard of stroke was found between patients with PC who did and did not receive ADT (hazard ratio, 1.09; 95% confidence interval, 0.80-1.50). Conclusions There was no significant difference in the risk of stroke between ethnic Chinese patients with PC who did and did not receive ADT, after adjusting for potential confounders.

KW - androgen deprivation therapy

KW - epidemiology

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84858025902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858025902&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2011.10459.x

DO - 10.1111/j.1464-410X.2011.10459.x

M3 - Article

VL - 109

SP - 1001

EP - 1005

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 7

ER -